The value of platinum compounds in non-small-cell lung cancer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The value of platinum compounds has come into question with the advent of newer chemotherapy agents in the management of patients with advanced non-small-cell lung cancer. These newer agents, which include the taxanes, topoisomerase I inhibitors, gemcitabine, and vinorelbine, appear to have higher single-agent response rates and more favorable toxicity profiles when compared to the platinum compounds. However, the toxicity of the platinum compounds is now minimized with the advent of more effective antiemetics. In addition, phase III clinical trials have demonstrated that the strategy of cisplatin dose intensity and prolonged duration of therapy with platinum compounds does not improve overall survival; therefore, moderate doses of cisplatin and a shorter duration of therapy can be given to further decrease toxicity. Furthermore, while phase II trials utilizing nonplatinum-based combination chemotherapy appear to demonstrate superior response rates and survival in comparison to platinum-based doublets, results of phase III trials have demonstrated no improvement in survival. Platinum combination chemotherapy remains the standard approach for stage IV non-small-cell lung cancer. More substantial advances will likely be made with novel molecular targeted therapy, such as the epidermal growth factor receptor inhibitors, which demonstrate synergy with the platinum compounds.

Original languageEnglish
Pages (from-to)249-253
Number of pages5
JournalClinical Lung Cancer
Volume3
Issue number4
StatePublished - 2002

Fingerprint

Platinum Compounds
Non-Small Cell Lung Carcinoma
gemcitabine
Combination Drug Therapy
Platinum
Cisplatin
Molecular Targeted Therapy
Topoisomerase I Inhibitors
Taxoids
Phase III Clinical Trials
Antiemetics
Survival
Epidermal Growth Factor Receptor
Survival Rate
Drug Therapy
Therapeutics

Keywords

  • Chemotherapy
  • Cisplatin
  • Gemcitabine
  • Paclitaxel
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

The value of platinum compounds in non-small-cell lung cancer. / Hanna, Nasser; Einhorn, Lawrence.

In: Clinical Lung Cancer, Vol. 3, No. 4, 2002, p. 249-253.

Research output: Contribution to journalArticle

@article{8579ccbd5b3e4843b82bb969cb1969d6,
title = "The value of platinum compounds in non-small-cell lung cancer",
abstract = "The value of platinum compounds has come into question with the advent of newer chemotherapy agents in the management of patients with advanced non-small-cell lung cancer. These newer agents, which include the taxanes, topoisomerase I inhibitors, gemcitabine, and vinorelbine, appear to have higher single-agent response rates and more favorable toxicity profiles when compared to the platinum compounds. However, the toxicity of the platinum compounds is now minimized with the advent of more effective antiemetics. In addition, phase III clinical trials have demonstrated that the strategy of cisplatin dose intensity and prolonged duration of therapy with platinum compounds does not improve overall survival; therefore, moderate doses of cisplatin and a shorter duration of therapy can be given to further decrease toxicity. Furthermore, while phase II trials utilizing nonplatinum-based combination chemotherapy appear to demonstrate superior response rates and survival in comparison to platinum-based doublets, results of phase III trials have demonstrated no improvement in survival. Platinum combination chemotherapy remains the standard approach for stage IV non-small-cell lung cancer. More substantial advances will likely be made with novel molecular targeted therapy, such as the epidermal growth factor receptor inhibitors, which demonstrate synergy with the platinum compounds.",
keywords = "Chemotherapy, Cisplatin, Gemcitabine, Paclitaxel, Vinorelbine",
author = "Nasser Hanna and Lawrence Einhorn",
year = "2002",
language = "English",
volume = "3",
pages = "249--253",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - The value of platinum compounds in non-small-cell lung cancer

AU - Hanna, Nasser

AU - Einhorn, Lawrence

PY - 2002

Y1 - 2002

N2 - The value of platinum compounds has come into question with the advent of newer chemotherapy agents in the management of patients with advanced non-small-cell lung cancer. These newer agents, which include the taxanes, topoisomerase I inhibitors, gemcitabine, and vinorelbine, appear to have higher single-agent response rates and more favorable toxicity profiles when compared to the platinum compounds. However, the toxicity of the platinum compounds is now minimized with the advent of more effective antiemetics. In addition, phase III clinical trials have demonstrated that the strategy of cisplatin dose intensity and prolonged duration of therapy with platinum compounds does not improve overall survival; therefore, moderate doses of cisplatin and a shorter duration of therapy can be given to further decrease toxicity. Furthermore, while phase II trials utilizing nonplatinum-based combination chemotherapy appear to demonstrate superior response rates and survival in comparison to platinum-based doublets, results of phase III trials have demonstrated no improvement in survival. Platinum combination chemotherapy remains the standard approach for stage IV non-small-cell lung cancer. More substantial advances will likely be made with novel molecular targeted therapy, such as the epidermal growth factor receptor inhibitors, which demonstrate synergy with the platinum compounds.

AB - The value of platinum compounds has come into question with the advent of newer chemotherapy agents in the management of patients with advanced non-small-cell lung cancer. These newer agents, which include the taxanes, topoisomerase I inhibitors, gemcitabine, and vinorelbine, appear to have higher single-agent response rates and more favorable toxicity profiles when compared to the platinum compounds. However, the toxicity of the platinum compounds is now minimized with the advent of more effective antiemetics. In addition, phase III clinical trials have demonstrated that the strategy of cisplatin dose intensity and prolonged duration of therapy with platinum compounds does not improve overall survival; therefore, moderate doses of cisplatin and a shorter duration of therapy can be given to further decrease toxicity. Furthermore, while phase II trials utilizing nonplatinum-based combination chemotherapy appear to demonstrate superior response rates and survival in comparison to platinum-based doublets, results of phase III trials have demonstrated no improvement in survival. Platinum combination chemotherapy remains the standard approach for stage IV non-small-cell lung cancer. More substantial advances will likely be made with novel molecular targeted therapy, such as the epidermal growth factor receptor inhibitors, which demonstrate synergy with the platinum compounds.

KW - Chemotherapy

KW - Cisplatin

KW - Gemcitabine

KW - Paclitaxel

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0036308506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036308506&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 249

EP - 253

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 4

ER -